Compare
Astrana Health, Inc. vs FTI Consulting, Inc vs Genpact Ltd vs ICF International, Inc.
| Latest fiscal year | Astrana Health, Inc. ASTH | FTI Consulting, Inc FCN | Genpact Ltd G | ICF International, Inc. ICFI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.18B | $3.79B | $5.08B | $1.87B |
| Revenue growth (YoY) | +56.4% | +2.4% | +6.6% | -7.3% |
| Gross margin | n/a | 32.1% | 36.0% | 37.2% (computed) |
| Operating margin | 2.5% | 10.3% | 14.8% | 7.8% |
| Net margin | 0.7% | 7.1% | 10.9% | 4.9% |
| Net income | $22.49M | $270.87M | $552.49M | $91.59M |
| EPS (Diluted) | $0.46 | $8.24 | $3.13 | $4.95 |
| Operating cash flow | $114.60M | $152.13M | $812.86M | $141.87M |
| Free cash flow | $104.49M | $93.60M | $734.65M | $120.21M |
| Cash & equivalents | $429.47M | $265.09M | $853.84M | $5.30M |
| Total assets | $2.22B | $3.49B | $5.84B | $2.05B |
| Total liabilities | $1.66B | $1.76B | $3.29B | $1.02B |
| Shareholders' equity | $779.29M | $1.73B | $2.55B | $1.03B |
| Return on year-end equity | 2.9% | 15.6% | 21.7% | 8.9% |
| Shares outstanding | 48.89M | 30.86M | 170.34M | 18.25M |
Revenue, most recent five fiscal years
| Fiscal year | Astrana Health, Inc. | FTI Consulting, Inc | Genpact Ltd | ICF International, Inc. |
|---|---|---|---|---|
| Latest | $3.18B Ended 2025-12-31 | $3.79B Ended 2025-12-31 | $5.08B Ended 2025-12-31 | $1.87B Ended 2025-12-31 |
| 1 year earlier | $2.03B Ended 2024-12-31 | $3.70B Ended 2024-12-31 | $4.77B Ended 2024-12-31 | $2.02B Ended 2024-12-31 |
| 2 years earlier | $1.39B Ended 2023-12-31 | $3.49B Ended 2023-12-31 | $4.48B Ended 2023-12-31 | $1.96B Ended 2023-12-31 |
| 3 years earlier | $1.14B Ended 2022-12-31 | $3.03B Ended 2022-12-31 | $4.37B Ended 2022-12-31 | $1.78B Ended 2022-12-31 |
| 4 years earlier | $773.91M Ended 2021-12-31 | $2.78B Ended 2021-12-31 | $4.02B Ended 2021-12-31 | $1.55B Ended 2021-12-31 |